Although current clinical practices involve the measurement of T-CHOL, LDL, HDL, and triglycerides to inform treatment decisions, the results of the current study suggest that the precursor protein ApoB and, to a lesser extent, ApoA-I may be stronger predictors of subclinical atherosclerosis, and therefore may be helpful parameters to use in clinical practice. This evidence concerns the gene APOB and atherosclerosis.